Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BFNHOTCMKTS:BNOEFNASDAQ:HOTHOTCMKTS:NICXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFNHBioForce Nanosciences$0.45-9.5%$0.52$0.16▼$1.88$15.09M-1.221,288 shs600 shsBNOEFBionomics$0.00-43.3%$0.00$0.00▼$0.06$4.45M1.86140,299 shs22,900 shsHOTHHoth Therapeutics$1.17-1.7%$1.01$0.58▼$3.80$15.72M0.553.69 million shs274,585 shsNICXFNicox$0.25$0.25$0.25▼$0.28$17.23M0.29N/AN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFNHBioForce Nanosciences0.00%0.00%-10.00%-20.09%-75.68%BNOEFBionomics0.00%0.00%0.00%0.00%0.00%HOTHHoth Therapeutics-1.68%-12.69%+36.11%+13.59%+27.17%NICXFNicox0.00%0.00%0.00%0.00%-43.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFNHBioForce NanosciencesN/AN/AN/AN/AN/AN/AN/AN/ABNOEFBionomicsN/AN/AN/AN/AN/AN/AN/AN/AHOTHHoth Therapeutics2.8722 of 5 stars3.65.00.00.02.30.00.6NICXFNicoxN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFNHBioForce Nanosciences 0.00N/AN/AN/ABNOEFBionomics 0.00N/AN/AN/AHOTHHoth Therapeutics 3.25Buy$4.00241.88% UpsideNICXFNicox 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BNOEF, BFNH, HOTH, and NICXF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFNHBioForce NanosciencesN/AN/AN/AN/A($0.07) per shareN/ABNOEFBionomicsN/AN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/ANICXFNicox$5.52M3.12N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFNHBioForce Nanosciences-$490K-$0.04N/A∞N/AN/AN/A-30,513.47%8/5/2025 (Estimated)BNOEFBionomicsN/AN/A0.00∞N/AN/AN/AN/AN/AHOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)NICXFNicox-$29.25MN/A0.00∞N/AN/AN/AN/A7/16/2025 (Estimated)Latest BNOEF, BFNH, HOTH, and NICXF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BFNHBioForce NanosciencesN/A-$0.03N/A-$0.03N/AN/A5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A4/8/2025Q4 2024BFNHBioForce NanosciencesN/A-$0.01N/A-$0.01N/AN/A3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFNHBioForce NanosciencesN/AN/AN/AN/AN/ABNOEFBionomicsN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ANICXFNicoxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFNHBioForce NanosciencesN/A0.050.05BNOEFBionomicsN/AN/AN/AHOTHHoth TherapeuticsN/A15.0915.08NICXFNicoxN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFNHBioForce NanosciencesN/ABNOEFBionomicsN/AHOTHHoth Therapeutics7.08%NICXFNicoxN/AInsider OwnershipCompanyInsider OwnershipBFNHBioForce Nanosciences39.54%BNOEFBionomicsN/AHOTHHoth Therapeutics6.92%NICXFNicoxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFNHBioForce Nanosciences233.52 million20.27 millionNot OptionableBNOEFBionomicsN/A1.31 billionN/ANot OptionableHOTHHoth Therapeutics413.21 million12.30 millionNot OptionableNICXFNicox2868.92 millionN/ANot OptionableBNOEF, BFNH, HOTH, and NICXF HeadlinesRecent News About These CompaniesNicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representativeJune 6, 2025 | santelog.comSNICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finanznachrichten.deNicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finance.yahoo.comNicox releases results from Whistler phase 3b trial in IOP lowering eye dropsMay 15, 2025 | ophthalmologytimes.comONicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma TrialMay 14, 2025 | finance.yahoo.comNicOx S.A.May 10, 2025 | barrons.comNicox Provides Full Year 2024 Financial ResultsApril 30, 2025 | finance.yahoo.comNicox announces last patient completed final visit in Whistler Phase 3b clinical trialMarch 24, 2025 | ophthalmologytimes.comONICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialMarch 19, 2025 | finanznachrichten.deNicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialMarch 19, 2025 | markets.businessinsider.comNicox presents new analysis from the NCX 470 Mont Blanc trialMarch 7, 2025 | thepharmaletter.comTNICOX SA: Nicox Extends Cash Runway into Q4 2025March 6, 2025 | finanznachrichten.deNicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development UpdateMarch 3, 2025 | markets.businessinsider.comNicox Announces Scientific Presentation and Conference Attendance in H1 2025January 29, 2025 | markets.businessinsider.comNiconico's Mature Illustration Service Niconico Shunga to End ServiceJanuary 18, 2025 | animenewsnetwork.comANiconico Shunga Latest Japanese Retailer to Shutter Because of “Current Social Environment”January 18, 2025 | otakuusamagazine.comOJapanese publisher Kadokawa paid $3 million to Russia-linked hacker group after cyberattackDecember 12, 2024 | msn.comSquare Enix Lays Out Streaming Rules for Dragon Quest 3 RemakeNovember 9, 2024 | gamerant.comGBeijing says it has consistent US policy, as Asian nations react to Trump’s winNovember 7, 2024 | straitstimes.comSRe:Zero Season 3 Episode 6 Release Date, Where To Stream, Expected Plot And MoreNovember 6, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNOEF, BFNH, HOTH, and NICXF Company DescriptionsBioForce Nanosciences OTCMKTS:BFNH$0.45 -0.05 (-9.47%) As of 06/25/2025 02:45 PM EasternBioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.Bionomics OTCMKTS:BNOEF$0.0034 0.00 (-43.33%) As of 09/19/2023Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Hoth Therapeutics NASDAQ:HOTH$1.17 -0.02 (-1.68%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.43%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Nicox OTCMKTS:NICXF$0.25 0.00 (0.00%) As of 06/25/2025Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
